Gastric acid hypersecretory states: Recent insights and advances

Current Gastroenterology Reports

Volumn 11, Issue 6, 2009, Pages 433-441

  Jensen, Robert T ^a   Osefo, Nauramy ^b   Ito, Tetsuhide ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CALVASCULIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GASTRIN; MERCAPTAMINE; OCTREOTIDE; PROTEIN P16; PROTON PUMP INHIBITOR; RADIOPHARMACEUTICAL AGENT; SECRETIN; SMAD4 PROTEIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN LU 177; UNCLASSIFIED DRUG;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTINOSIS; DELAYED DIAGNOSIS; DIARRHEA; DISEASE ASSOCIATION; DUODENUM ULCER; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; GASTRINOMA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; IDIOPATHIC DISEASE; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATICODUODENECTOMY; PEPTIC ULCER; REBOUND; REVIEW; STOMACH ACID HYPERSECRETION; STOMACH ACID SECRETION; STOMACH PH; SURVIVAL TIME; SYSTEMIC MASTOCYTOSIS; TUMOR LOCALIZATION; ZOLLINGER ELLISON SYNDROME;

CYSTAMINE; CYSTINOSIS; ENZYME INHIBITORS; GASTRIC ACID; GASTRINS; HISTAMINE; HUMANS; PROTON PUMP INHIBITORS; STOMACH DISEASES; ZOLLINGER-ELLISON SYNDROME;

EID: 72549108765     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0067-6     Document Type: Review

References (67)

1. M.L. Schubert D.A. Peura 2008 Control of gastric acid secretion in health and disease Gastroenterology 134 1842 1860 10.1053/j.gastro.2008.05.021 1:CAS:528:DC%2BD1cXosFGltr4%3D 18474247 (Pubitemid 351783299)
2. P. Roy D.J. Venzon K.M. Feigenbaum, et al. 2001 Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis: a prospective NIH study of 235 patients and review of the literature in 984 cases Medicine (Baltimore) 80 189 222 10.1097/00005792- 200105000-00005 1:STN:280:DC%2BD3MzhsFChsg%3D%3D (Pubitemid 32466460)
3. Jensen RT, Gardner JD: Gastrinoma. In The Pancreas: Biology, Pathobiology and Disease, edn 2. Edited by Go VLW, DiMagno EP, Gardner JD, et al. New York: Raven Press; 1993:931-978.
4. P. Roy D.J. Venzon H. Shojamanesh, et al. 2000 Zollinger-Ellison syndrome: clinical presentation in 261 patients Medicine (Baltimore) 79 379 411 10.1097/00005792-200011000-00004 1:STN:280:DC%2BD3M%2FntFKisg%3D%3D
5. J.M. Nieto J.R. Pisegna 2006 The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome Expert Opin Pharmacother 7 169 175 10.1517/14656566.7.2.169 1:CAS:528:DC%2BD28XotlGnsQ%3D%3D 16433582 (Pubitemid 43263256)
6. D.C. Metz R.T. Jensen 2008 Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Gastroenterology 135 1469 1492 10.1053/j.gastro. 2008.05.047 1:CAS:528:DC%2BD1cXhsVOhtb3K 18703061
7. E.C. Ellison J.A. Johnson 2009 The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations Curr Probl Surg 46 13 106 10.1067/j.cpsurg.2008.09.001 19059523
8. R.T. Jensen 2000 Gastrointestinal abnormalities and involvement in systemic mastocytosis Oncol Hematol Clin North Am 14 579 623 10.1016/S0889-8588(05)70298-7 1:STN:280:DC%2BD3M%2Fls1ejsg%3D%3D
9. Jensen RT: Treatment of pancreatic Zollinger-Ellison syndrome and other gastric hypersecretory states. In Therapy of Digestive Disorders. A companion to Sleisenger and Fordtran's Gastrointestinal and Liver Diseases, edn 21. Edited by Wolfe MM. Philadelphia: WB Saunders; 2000:169-187.
10. M.J. Berna K.M. Hoffmann J. Serrano, et al. 2006 Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature Medicine (Baltimore) 85 295 330 10.1097/01.md.0000236956. 74128.76 1:CAS:528:DC%2BD28Xht1SmtrrE (Pubitemid 44772671)
11. F. Gibril M. Schumann A. Pace R.T. Jensen 2004 Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature Medicine (Baltimore) 83 43 83 10.1097/01.md.0000112297.72510.32 (Pubitemid 38124855)
12. R.T. Jensen M.J. Berna M.D. Bingham J.A. Norton 2008 Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies Cancer 113 7Suppl 1807 1843 18798544
13. R. Arnold 2007 Diagnosis and differential diagnosis of hypergastrinemia Wien Klin Wochenschr 119 564 569 10.1007/s00508-007-0878-0 1:CAS:528: DC%2BD1cXksl2rug%3D%3D 17985088 (Pubitemid 350060659)
14. V.D. Corleto B. Annibale F. Gibril, et al. 2001 Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 15 1555 1561 10.1046/j.1365-2036.2001.01085.x 1:STN:280:DC%2BD3Mrlt1enuw%3D%3D 11563994 (Pubitemid 32912397)
15. S.V. Murugesan A. Varro D.M. Pritchard 2009 Review article: strategies to determine whether hypergastrinaemia is due to Zollinger Ellison syndrome rather than a more common benign cause Aliment Pharmacol Ther 29 1055 1068 10.1111/j.1365-2036.2009.03976.x 1:CAS:528:DC%2BD1MXmtVOltrc%3D 19226290
16. M.J. Berna K.M. Hoffmann S.H. Long, et al. 2006 Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features Medicine (Baltimore) 85 331 364 10.1097/MD.0b013e31802b518c 1:CAS:528:DC%2BD28Xht1SmtrrF (Pubitemid 44772672)
17. M. Banasch F. Schmitz 2007 Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors Wien Klin Wochenschr 119 573 578 10.1007/s00508-007-0884-2 1:CAS:528:DC%2BD1cXksl2qsg%3D%3D 17985090 (Pubitemid 350060665)
18. R.T. Jensen 2006 Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas Basic Clin Pharmacol Toxicol 98 4 19 10.1111/j.1742-7843.2006.pto-378.x 1:CAS:528:DC%2BD28XhsFegsLk%3D 16433886
19. B.I. Hirschowitz J. Simmons J. Mohnen 2001 Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study Aliment Pharmacol Ther 15 1795 1806 10.1046/j.1365-2036.2001.01097.x 1:CAS:528:DC%2BD3MXosVWqtLw%3D 11683694 (Pubitemid 33001144)
20. W.S. Dhillo C.N. Jayasena C.J. Lewis, et al. 2006 Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists Ann Clin Biochem 43 153 155 10.1258/000456306776021607 1:CAS:528:DC%2BD28Xjslaitb4%3D 16536918 (Pubitemid 43332337)
21. L. Agreus T. Storskrubb P. Aro, et al. 2009 Clinical use of protonpump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population Scand J Gastroenterol 44 564 570 10.1080/00365520902745062 1:CAS:528: DC%2BD1MXltV2jt7o%3D 19263272
22. D.S. Oh H.S. Wang G.V. Ohning J.R. Pisegna 2006 Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome Clin Gastroenterol Hepatol 4 1467 1473 10.1016/j.cgh.2006.08.015 17101299 (Pubitemid 44880025)
23. S.H. Long M.J. Berna M. Thill, et al. 2007 Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results J Clin Endocrinol Metab 92 4394 4402 10.1210/jc.2007-0986 1:CAS:528:DC%2BD2sXhtlartbvK 17711922 (Pubitemid 350074762)
24. J.A. Goldman W.P. Blanton D.W. Hay M.M. Wolfe 2009 False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy Clin Gastroenterol Hepatol 7 600 602 10.1016/j.cgh.2009.02.018 19245850
25. C. Shibata Y. Funayama K. Fukushima, et al. 2008 The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome J Gastrointest Surg 12 344 349 10.1007/s11605-007-0372-z 17929104
26. J.A. Norton H.A. Alexander D.L. Fraker, et al. 2003 Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: a prospective study Ann Surg 237 650 659 10.1097/00000658-200305000-00007 12724631 (Pubitemid 38174531)
27. Y. Ishikawa H. Yoshida Y. Mamada, et al. 2008 Curative resection of primary hepatic gastrinoma Hepatogastroenterology 55 2224 2227 19260510
28. H.C. Weber D.J. Venzon J.T. Lin, et al. 1995 Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study Gastroenterology 108 1637 1649 10.1016/0016-5085(95)90124-8 1:STN:280:DyaK2M3osF2ktQ%3D%3D 7768367
29. J.A. Norton H.R. Alexander D.L. Fraker, et al. 2004 Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 239 617 626 10.1097/01.sla.0000124290.05524.5e 15082965 (Pubitemid 38525632)
30. F. Yu D.J. Venzon J. Serrano, et al. 1999 Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome J Clin Oncol 17 615 630 1:STN:280: DyaK1M7nvVKqsA%3D%3D 10080607
31. F. Gibril D.J. Venzon J.V. Ojeaburu, et al. 2001 Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form J Clin Endocrinol Metab 86 5282 5293 10.1210/jc.86.11.5282 1:CAS:528:DC%2BD3MXos1KqsLs%3D 11701693 (Pubitemid 33070249)
32. A.O. Vortmeyer S. Huang I. Lubensky Z. Zhuang 2004 Non-islet origin of pancreatic islet cell tumors J Clin Endocrinol Metab 89 1934 1938 10.1210/jc.2003-031575 1:CAS:528:DC%2BD2cXjt1eltb8%3D 15070966 (Pubitemid 38507955)
33. A. Perren M. Anlauf T. Henopp, et al. 2007 Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas J Clin Endocrinol Metab 92 1118 1128 10.1210/jc.2006-1944 1:CAS:528:DC%2BD2sXjtlGmsL8%3D 17179192 (Pubitemid 46465691)
34. M. Anlauf A. Perren G. Kloppel 2007 Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance Pathobiology 74 279 284 10.1159/000105810 17890894 (Pubitemid 47450573)
35. P. Capelli G. Martignoni F. Pedica, et al. 2009 Endocrine neoplasms of the pancreas: pathologic and genetic features Arch Pathol Lab Med 133 350 364 19260741
36. M.J. Berna B. Annibale M. Marignani, et al. 2008 A prospective study of gastric carcinoids and enterochromaffin-like cells changes in multple endocrine neoplaisa type 1 and Zollinger-Ellison syndrome: identification of risk factors J Clin Endocrinol Metab 93 1582 1591 10.1210/jc.2007-2279 1:CAS:528: DC%2BD1cXlvFWhu7Y%3D 18270260 (Pubitemid 351656492)
37. J.A. Norton D.J. Venzon M.J. Berna, et al. 2008 Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1), and Zollinger-Ellison syndrome (ZES): long-term outcome of a more virulent form of HPT Ann Surgery 247 501 510 10.1097/SLA.0b013e31815efda5
38. J.A. Norton R.T. Jensen 2004 Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome Ann Surg 240 757 773 10.1097/01.sla.0000143252.02142.3e 15492556 (Pubitemid 39425767)
39. K.M. Hoffmann F. Gibril L.K. Entsuah, et al. 2006 Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus J Clin Endocrinol Metab 91 204 212 10.1210/jc.2005-1349 1:CAS:528:DC%2BD28Xms1antA%3D%3D 16249283 (Pubitemid 43069139)
40. F. Gibril R.T. Jensen 2004 Diagnostic uses of radiolabeled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors Dig Liver Dis 36 S106 S120 10.1016/j.dld.2003.11.024 1:CAS:528:DC%2BD2cXjsFOns7w%3D 15077919 (Pubitemid 41115498)
41. Berna MJ, Jensen RT: Uses of radiolabeled somatostatin receptor analogues in diagnosis of gastrointestinal neuroendocrine tumors. In A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Edited by Modlin IM, Oberg K. Hanover: Felsenstein CCCP; 2007:328-339.
42. R.D. Niederkohr I.R. McDougall 2007 Incidental gallbladder visualization on nonhepatobiliary nuclear medicine studies: case series and review of the literature Clin Nucl Med 32 915 919 10.1097/RLU.0b013e31815976e0 18030040 (Pubitemid 350146467)
43. J. Bunning S.H. Merchant L.A. Crooks M.F. Hartshorne 2007 Indium-111 pentetreotide uptake by pancreatic polypeptide cell hyperplasia: potential pitfall in somatostatin receptor scintigraphy Pancreas 35 372 375 10.1097/mpa.0b013e31811ea2a2 18090246 (Pubitemid 350307383)
44. P.H. Kann 2007 The value of endoscopic ultrasound in localizing gastrinoma Wien Klin Wochenschr 119 585 587 10.1007/s00508-007-0880-6 17985092 (Pubitemid 350060661)
45. A. Sundin U. Garske H. Orlefors 2007 Nuclear imaging of neuroendocrine tumours Best Pract Res Clin Endocrinol Metab 21 69 85 10.1016/j.beem.2006.12.003 1:CAS:528:DC%2BD2sXjsVSqt7g%3D 17382266 (Pubitemid 46421900)
46. M. Gabriel C. Decristoforo D. Kendler, et al. 2007 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF 17401086 (Pubitemid 47571404)
47. R.C. Franz H.O. Penzhorn 2007 Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome? S Afr J Surg 45 58 60 1:STN:280:DC%2BD2svlslGqsg%3D%3D 17674564
48. A. Morocutti M. Merrouche T. Bjaaland, et al. 2006 An openlabel study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion Aliment Pharmacol Ther 24 1439 1444 10.1111/j.1365-2036. 2006.03137.x 1:CAS:528:DC%2BD28Xhtlant7vJ 17081164 (Pubitemid 44657120)
49. D.C. Metz G.M. Comer E. Soffer, et al. 2006 Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions Aliment Pharmacol Ther 23 437 444 10.1111/j.1365-2036.2006.02762.x 1:CAS:528:DC%2BD28Xit1KjsL4%3D 16423003 (Pubitemid 43382024)
50. D.C. Metz M.B. Sostek P. Ruszniewski, et al. 2007 Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion Am J Gastroenterol 102 2648 2654 10.1111/j.1572-0241.2007.01509.x 1:CAS:528:DC%2BD1cXkvVCksg%3D%3D 17764495 (Pubitemid 350179329)
51. B. Termanini F. Gibril V.E. Sutliff III, et al. 1998 Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome Am J Med 104 422 430 10.1016/S0002-9343(98)00087-4 1:CAS:528:DyaK1cXktVSjtbc%3D 9626024 (Pubitemid 28274845)
52. B.I. Hirschowitz J. Worthington J. Mohnen 2008 Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors Aliment Pharmacol Ther 27 1110 1121 10.1111/j.1365-2036.2008.03658.x 1:CAS:528:DC%2BD1cXotFamu7o%3D 18315582 (Pubitemid 351614880)
53. Y.X. Yang J.D. Lewis S. Epstein D.C. Metz 2006 Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2947 2953 10.1001/jama.296.24.2947 1:CAS:528:DC%2BD2sXnvVGn 17190895 (Pubitemid 46021498)
54. K. Lorenz H. Dralle 2007 Surgical treatment of sporadic gastrinoma Wien Klin Wochenschr 119 597 601 10.1007/s00508-007-0882-4 17985095 (Pubitemid 350060663)
55. J.A. Norton R.T. Jensen 2007 Role of surgery in Zollinger-Ellison syndrome J Am Coll Surg 205 S34 S37 10.1016/j.jamcollsurg.2007.06.320 17916516 (Pubitemid 47488912)
56. J.A. Norton D.L. Fraker H.R. Alexander, et al. 2006 Surgery increases survival in patients with gastrinoma Ann Surg 244 410 419 16926567
57. U. Plockinger B. Wiedenmann 2005 Management of metastatic endocrine tumours Best Pract Res Clin Gastroenterol 19 553 576 10.1016/j.bpg.2005.02.013 1:STN:280:DC%2BD2MrgvFCjtw%3D%3D 16183527 (Pubitemid 41447718)
58. D.J. Kwekkeboom J.J. Teunissen W.H. Bakker, et al. 2005 Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors J Clin Oncol 23 2754 2762 10.1200/JCO.2005.08.066 1:CAS:528:DC%2BD2MXktleqtrk%3D 15837990 (Pubitemid 46179465)
59. J.C. Yao 2007 Molecular targeted therapy for carcinoid and islet-cell carcinoma Best Pract Res Clin Endocrinol Metab 21 163 172 10.1016/j.beem.2007. 01.006 1:CAS:528:DC%2BD2sXjsVSqtrc%3D 17382271 (Pubitemid 46421905)
60. M.H. Kulke H.J. Lenz N.J. Meropol, et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 3403 3410 10.1200/JCO.2007.15.9020 1:CAS:528:DC%2BD1cXpvVWitro%3D 18612155
61. J.C. Yao A.T. Phan D.Z. Chang, et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 4311 4318 10.1200/JCO.2008.16.7858 18779618
62. M.M. Patnaik M. Rindos P.A. Kouides, et al. 2007 Systemic mastocytosis: a concise clinical and laboratory review Arch Pathol Lab Med 131 784 791 17488167
63. W.C. Blonski D.A. Katzka G.R. Lichtenstein D.C. Metz 2005 Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease Eur J Gastroenterol Hepatol 17 441 444 10.1097/00042737-200504000-00008 15756097 (Pubitemid 40477514)
64. A.A. Desai J.E. McGuigan P. Draganov 2005 Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor Int J Gastrointest Cancer 35 157 161 10.1385/IJGC:35:2:157 15879632
65. G. Qvigstad H. Waldum 2004 Rebound hypersecretion after inhibition of gastric acid secretion Basic Clin Pharmacol Toxicol 94 202 208 1:CAS:528:DC%2BD2cXksVyktro%3D 15125689
66. N.G. Hunfeld W.P. Geus E.J. Kuipers 2007 Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors Aliment Pharmacol Ther 25 39 46 1:CAS:528:DC%2BD2sXht12qurw%3D 17229219
67. R. Dohil M. Fidler B. Barshop, et al. 2005 Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis Pediatr Nephrol 20 1786 1793 10.1007/s00467-005-2027-1 16133039 (Pubitemid 41722966)